Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era

Japanese Journal of Clinical Oncology

Volumn 43, Issue 4, 2013, Pages 404-409

  Takaoka, Ei Ichiro ^a   Matsui, Yoshiyuki ^b   Inoue, Takamitsu ^c   Miyazaki, Jun ^a   Nakashima, Masakazu ^b   Kimura, Tomokazu ^a   Oikawa, Takehiro ^a   Kawai, Koji ^a   Yoshimura, Koji ^b   Habuchi, Tomonori ^c   Ogawa, Osamu ^b   Nishiyama, Hiroyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c AKITA UNIVERSITY   (Japan)

Author keywords

High grade T1 bladder cancer; Non muscle invasive bladder cancer; Second TUR

Indexed keywords

ADULT; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CARCINOMA IN SITU; CYSTECTOMY; CYSTOSCOPY; DISTANT METASTASIS; ECHOGRAPHY; FEMALE; HUMAN; INTRAVENOUS PYELOGRAPHY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NON MUSCLE INVASIVE BLADDER CANCER; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; URINE CYTOLOGY;

ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; RETROSPECTIVE STUDIES; RISK FACTORS; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84875801525     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt016     Document Type: Article

References (24)

1. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009;56:430-42.
2. Kurth KH. Natural history and prognosis of untreated and treated superficial bladder cancer. In: Pagano F, Fair WR, Bassi P, editors. Superficial Bladder Cancer. Oxford: Isis Medical Media Ltd., 1997;42-56.
3. Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 1997;158:62-7.
4. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57:60-70.
5. NCCN clinical guidelines in oncology. Bladder cancer 2012.
6. UICC. TNM classification of Malignant Tumors. 6th edn. New York: Wiley Liss 2002.
7. Eble JN, Sauter G, Epstein JE, Sesterhenn IA. Tumours of the Urinary System and Male Genital Organs (World Health Organization Classification of Tumours). Lyon: IARC Press 2004.
8. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59:997-1008.
9. Herr HW, Donat SM. Quality control in transurethral resection of bladder tumors. BJU Int 2008;102:1242-6.
10. rauers A, Buettner R, Jakse G. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early? J Urol 2001;165:808-10.
11. Divrik RT, Sahin AF, Yildirim U, Altok M, Zorlu F. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial. Eur Urol 2010;58:185-90.
12. Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316-8.
13. Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220-3.
14. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006;97:1199-201.
15. Han KS, Joung JY, Cho KS, et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer: the referral cancer center experience and review of the literature. J Endourol 2008;22:2699-704.
16. Ali MH, Ismail IY, Eltobgy A, Gobeish A. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cancer. J Endourol 2010;24:2047-50.
17. Jakse G, Algaba F, Malmstrom PU, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: Why? Eur Urol 2004;45: 539-46.
18. Grimm MO, Steinhoff C, Simon X, Spiegelhalder P, Ackermann R, Vogeli TA. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170:433-7.
19. Herr HW, Donat SM, Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? J Urol 2007;177:75-9.
20. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49: 466-77.
21. Segal R, Yafi FA, Brimo F, Tanguay S, Aprikian A, Kassouf W. Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 2012;109:1026-30.
22. Gomez JF, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with Bacillus Calmette-Guerin: The CUETO Scoring Model. J Urol 2009;182:2195-203.
23. Guevara A, Salomon L, Allory Y, et al. The role of tumor-free status in repeat resection before intravesical Bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. J Urol 2010;183:2161-4.
24. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009;56:903-10.